BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma

Biosyngen has obtained FDA IND clearance of BRG01 for Phase I/II clinical trials against Nasopharyngeal Cancer

Prior to this approval from the US FDA, Biosyngen's BRG01 was granted IND by China CDE on December 14th, 2022. In addition, China CDE has acknowledged...

February 18, 2023 | News

Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial

BA2101 is the first long-acting anti-IL-4Rα monoclonal antibody that enters the clinical trial stage in the country. It is intended to be used for tr...

February 16, 2023 | News

Boan Biotech's Investigational Anti-CD25 Antibody BA1106 Administered for First Patient in Phase I Clinical Trial

BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China for treating solid tumors. Focusing on key therapeutic a...

February 13, 2023 | News

Nectin Therapeutics to Collaborate with Merck on a Clinical Trial of Anti-PVR Antibody NTX1088

Nectin Therapeutics Ltd. (Nectin), a biotechnology company developing novel targeted immunotherapies that address resistance to approved immune oncology tr...

February 08, 2023 | News

Amjevita™ (Adalimumab-atto), First Biosimilar to Humira®, Now Available in the United States

Amgen (NASDAQ:AMGN) announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the Un...

February 01, 2023 | News

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the cont...

January 23, 2023 | News

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a g...

January 23, 2023 | News

Pharma Industry Trend Brief: 2023 Manufacturing Trends

Worried about what the future holds for the pharmaceutical industry? This trend brief examines how manufacturers can take advantage of mo...

January 18, 2023 | News

FDA Accepts GMP Plasmid DMF of OBiO Technology

OBiO Technology (Shanghai) Corp., Ltd. ('OBiO', 688238.SH), a gene and cell therapy-focused contract research organization (CRO) and contract development a...

January 17, 2023 | News

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma Inc Announces Three Key Additions to Scientific and Clinical Expert Committee FSD Pharma Inc Announces It Is Investigating Other Products Addre...

January 10, 2023 | News

Sirio Pharma Successfully Completes the Acquisition of Best Formulations

"Our vision is to become an innovative leader in the field of nutrition and health, and the first choice of our customers”, said Patrick Lin, Chairma...

January 09, 2023 | News

Avantor® and Catalent Enter into Multi-Year Supply and Services Agreement

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologi...

January 09, 2023 | News

Sartorius Collaborates with RoosterBio to Advance Downstream Purification Processes for the Manufacture of Exosomes

Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - ...

January 06, 2023 | News

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

According to the collaboration agreements, WuXi XDC will actively promote GeneQuantum’s proprietary iLDC (intelligent Ligase-dependent Conjugation) a...

December 28, 2022 | News

Stay Connected